Get the Stockscreener App
190.66
1.92%
-3.6698
Illumina Inc stock is traded at $190.66, with a volume of 1.70M.
It is down -1.92% in the last 24 hours and up +17.42% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$194.33
Open:
$193.92
24h Volume:
1.70M
Relative Volume:
0.96
Market Cap:
$28.84B
Revenue:
$4.39B
Net Income/Loss:
$853.00M
P/E Ratio:
34.60
EPS:
5.5097
Net Cash Flow:
$556.00M
1W Performance:
+8.40%
1M Performance:
+17.42%
6M Performance:
+26.95%
1Y Performance:
+96.19%
1-Day Range:
$189.09
$196.66
1-Week Range:
$175.60
$196.66
52-Week Range:
$88.00
$196.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, NTRA, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
190.60 | 29.40B | 4.39B | 853.00M | 556.00M | 5.5097 |
TMO
Thermo Fisher Scientific Inc
|
513.81 | 194.52B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
193.38 | 137.04B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
565.80 | 44.57B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
281.67 | 40.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
WAT
Waters Corp
|
374.27 | 37.20B | 3.77B | 449.25M | 240.68M | 7.8556 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina stock stays tied to its sequencing business. Investors watch the next filing. - AD HOC NEWS
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking Illumina (NASDAQ:ILMN) - TradingView
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina Looks To Duck DNA Rival's Renewed Antitrust Case - Law360
Weekly Recap: Axelios challenges Illumina and Guggenheim lifts ILMN target to $200 - TradingView
Illumina, Inc. (ILMN) Stock Analysis: Navigating Potential Downsides Amidst 33.82% ROE - DirectorsTalk Interviews
Environmental DNA Market Set to Surge to USD 5.61 Billion by 2031 with 10.2% CAGR - GlobeNewswire Inc.
iSeq 100 System from Illumina Inc.compact benchtop sequencer targets cost-conscious US labs - AD HOC NEWS
Is Illumina (ILMN) Quietly Recasting Its Clinical Genomics Strategy With Eli Lilly’s R&D Chief on Board? - simplywall.st
Illumina Inc. focuses on sequencing technology leadership as investors watch long-term growth driver - AD HOC NEWS
Illumina SVP Jakob Wedel Christensen sells $97,328 in stock - Investing.com
Illumina Inc. focuses on sequencing technology as investors assess long-term growth - AD HOC NEWS
Should You Continue to Hold ILMN Stock in Your Portfolio? - TradingView
Price to sales forward of Illumina, Inc. – NASDAQ:ILMN - TradingView
Form 4 Illumina Inc For: 2 July By Investing.com - Investing.com Canada
Illumina (ILMN) director takes 2026 board fees entirely in stock - Stock Titan
[Form 4] ILLUMINA, INC. Insider Trading Activity - Stock Titan
ILMNIllumina Inc Volatility & Greeks - Finviz
Loomis Sayles Growth Fund's Illumina Inc(ILMN) Holding History - GuruFocus
Illumina Inc (ILMN) Stock Up 4.6% but GF Value Says Overvalued -- GF Score: 76/100 - GuruFocus
Illumina (ILMN) Gets Bernstein’s Market Perform Rating Amid NovaSeq X Recovery - Insider Monkey
Illumina stock hits 52-week high at 182.98 USD - Investing.com
Illumina stock hits 52-week high at 182.98 USD By Investing.com - Investing.com South Africa
Illumina Inc. focuses on sequencing and clinical genomics as investors watch long term growth - AD HOC NEWS
Piper Sandler raises Illumina stock price target on clinical strength - Investing.com
Why Illumina (ILMN) Stock Is Down Today - Yahoo Finance
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Roche takes on Illumina with new NGS system - MedTech Dive
Illumina: The Operational Turnaround Is Fully Priced In (NASDAQ:ILMN) - Seeking Alpha
Illumina earnings outlook and consensus, shares on NASDAQ - AD HOC NEWS
The NextSeq 2000 from Illumina Inc.mid-throughput sequencing aims for everyday lab work - AD HOC NEWS
Illumina Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Roche launches Axelios 1 sequencing platform to rival Illumina - BioWorld News
Roche takes aim at Illumina’s dominance with new gene sequencing machine - WNWN-FM
Roche takes aim at Illumina's dominance with new gene sequencing machine - Reuters
Price to earnings forward of Illumina, Inc. – TURQUOISE:ILMNN - TradingView
Illumina shares hold the 200 day line, analysts stay at Hold - AD HOC NEWS
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip - Yahoo Finance
Roche launches Axelios gene sequencer in a bid to loosen Illumina’s grip - WSAU
Roche Launches AXELIOS 1 Sequencer At $750,000, Targeting Illumina’s Market - insights.citeline.com
Illumina operations and strategy, DNA sequencing leader with NASDAQ-listed shares - AD HOC NEWS
Illumina, Inc. Actuals & Estimates (NASDAQ:ILMN) - TradingView
Illumina at a fresh 52-week high, Bernstein SocGen resumes coverage on the shares - Ad-hoc-news.de
Illumina, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh Actuals & Estimates (BMFBOVESPA:I1LM34) - TradingView
ILMN Forecast — Price Target — Prediction for 2027 - TradingView
Illumina Stock Is Up 32% in 2026: Has the GRAIL Recovery Already Been Priced In? - TIKR.com
Bernstein Maintains Illumina(ILMN.US) With Hold Rating, Announces Target Price $185 - Moomoo
Bernstein SocGen resumes Illumina stock coverage with market perform rating - Investing.com
Illumina chief legal officer sells shares, stock trades near 52-week high - Ad-hoc-news.de
Illumina Inc (ILMN) Institutional Confidence - TradingKey
Illumina, Inc. Actuals & Estimates (HAN:ILU) - TradingView
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.26%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):